Brief: Medicenna Presents Phase 1/2 Ability Study Data Highlighting Mdna11’S Favorable Clinical Profile At The 2022 Frontiers In Cancer Immunotherapy Meeting

Medicenna Therapeutics

11/05/2022 12:14

May 11 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PRESENTS PHASE 1/2 ABILITY STUDY DATA
HIGHLIGHTING
MDNA11’S FAVORABLE CLINICAL PROFILE AT THE 2022 FRONTIERS IN
CANCER IMMUNOTHERAPY MEETING
    * MEDICENNA THERAPEUTICS CORP - NEW DATA SHOW THAT MDNA11
BOOSTED
LYMPHOCYTE POPULATION BY 2-FOLD WITHOUT INDUCING SIGNIFICANT
INCREASES IN EOSINOPHILS
    * MEDICENNA THERAPEUTICS CORP - MDNA11 SELECTIVELY INCREASED
A
SUB-POPULATION OF ANTI-TUMOR ICOS+ CD8 T CELLS WITHOUT ENHANCING
PROLIFERATION
    * MEDICENNA THERAPEUTICS CORP - DOSE-DEPENDENT AND 3-FOLD
INCREASE
IN IMMUNE CELLS EXPRESSING GRANULYSIN

Source text for Eikon:  ID:nGNX2bdd7K 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))